` UBX (UNITY Biotechnology Inc) vs S&P 500 Comparison - Alpha Spread

UBX
vs
S&P 500

Over the past 12 months, UBX has underperformed S&P 500, delivering a return of -44% compared to the S&P 500's 9% growth.

Stocks Performance
UBX vs S&P 500

Loading
UBX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
UBX vs S&P 500

Loading
UBX
S&P 500
Difference
www.alphaspread.com

Performance By Year
UBX vs S&P 500

Loading
UBX
S&P 500
Add Stock

Competitors Performance
UNITY Biotechnology Inc vs Peers

S&P 500
UBX
ABBV
AMGN
GILD
VRTX
Add Stock

UNITY Biotechnology Inc
Glance View

Market Cap
13.6m USD
Industry
Biotechnology

Unity Biotechnology, Inc. operates as a biotechnology company. The company is headquartered in Brisbane California, California and currently employs 65 full-time employees. The company went IPO on 2018-05-03. The firm is engaged in developing a portfolio of programs targeting specific biological mechanisms implicated in diseases of aging. The firm is focused on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the opportunity to explore neurology and other therapeutic areas. The firm's product includes UBX1325, UBX2089 and UBX2050. UBX1325 is an advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration (AMD), and diabetic retinopathy (DR). UBX2089, an α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications. UBX2050 is investigating fully human anti-Tie2 agonist monoclonal antibody.

UBX Intrinsic Value
Not Available
Back to Top